NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells

Cancer Research

Volumn 62, Issue 1, 2002, Pages 213-218

  Zarour, Hassane M ^a   Coval, Kara ^a   Williams, Eileen ^a   Kirkwood, John M ^a   Maillere, Bernard ^b   Pouvelle Moratille, Sandra ^b   Castelli, Florence ^b   Brusic, Vladimir ^c   Land, Stephanie ^a   Bennouna, Jaafar ^a   Logan, Theodore ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b CEA SACLAY   (France)

^c INSTITUTE FOR INFOCOMM RESEARCH   (Singapore)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN NY ESO 1; UNCLASSIFIED DRUG;

ALLELISM; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EPITOPE MAPPING; GENETIC CODE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDE SYNTHESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE PROTEINS; PEPTIDE FRAGMENTS; PROTEINS; RECOMBINANT PROTEINS; TH1 CELLS; TH2 CELLS;

EID: 0036141435     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
2. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes
3. CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production
4. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
5. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
6. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
7. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells
8. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
9. A survey of the tumoral immune response of cancer patients to a panel of human tumor antigens
10. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
11. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
12. Detection of biotinylated cell surface receptors and MHC molecules in a capture ELISA: A rapid assay to measure endocytosis
13. HLA-DR restricted peptide candidates for bee venom immunotherapy
14. Complementarity and redundancy of the binding specificity of HLA-DRBI, -DRB3, -DRB4 and -DRB5 molecules
15. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens
16. Individual comparisons by ranking methods
17. Motifs and supermotifs for MHC class II binding peptides
18. Several common HLA-DR types share largely overlapping peptide binding repertoires
19. A malaria T-cell epitope recognized in association with most mouse and human MHC class 11 molecules
20. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides
21. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells
22. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen
23. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles
24. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo
25. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo
26. LAGE-1, a new gene with tumor specificity